TrialCancer2010

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.

Brian M Slomovitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.